$0.06
(Market cap
$3 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
0.1
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.2
-
Debt to Equity
0
-
Book Value
$29.2
-
EPS
$-222.7
-
Face value
--
-
Shares outstanding
819,709
9 Years Aggregate
CFO
$-88.61 Mln
EBITDA
$-123.86 Mln
Net Profit
$-129.38 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Genprex (GNPX)
| -90.5 | -52.6 | -78.5 | -98.1 | -94.4 | -87.8 | -- |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Genprex (GNPX)
| -95.9 | -90.6 | -84.1 | 10.7 | -68.4 | 1,196.9 | -70.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Genprex (GNPX)
|
3.7 | 3.0 | 0.0 | -16.5 | -- | -145 | 0.1 | 0.2 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 247.9 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Genprex (GNPX)
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations... with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. It also develops REQORSA Gene Therapy in Mesothelioma, Ras Inhibitor Resistant NSCLC, other tumor suppressor genes, and Glioblastoma, which is in preclinical studies. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive; New York University; UTHealth Houston; and University of Pittsburgh. The company also has a sponsored research agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that for the prediction of patient response to Reqorsa Gene Therapy. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas. Read more
-
Co-Founder, Chairman, President & CEO
Mr. John Rodney Varner
-
Co-Founder, Chairman, President & CEO
Mr. John Rodney Varner
-
Headquarters
Austin, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Genprex (GNPX)
What is the current share price of Genprex Inc (GNPX) Today?
The share price of Genprex Inc (GNPX) is $3.67 (NASDAQ) as of 28-Aug-2026 16:02 EDT. Genprex Inc (GNPX) has given a return of -94.36% in the last 3 years.
What is the current PB & PE ratio of Genprex Inc (GNPX)?
The P/E ratio of Genprex Inc (GNPX) is 0.10 times as on 28-Aug-2026.
The P/B ratio of Genprex Inc (GNPX) is 0.20 times as on 28-Aug-2026, a 96 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
0.00 |
0.01 |
2024 |
-0.44 |
5.71 |
2023 |
-0.01 |
0.05 |
2022 |
0.00 |
0.00 |
2021 |
0.00 |
0.00 |
What is the 52 Week High and Low of Genprex Inc (GNPX)?
The 52-week high and low of Genprex Inc (GNPX) are Rs 1,210.00 and Rs 3.57 as of 31-Aug-2026.
What is the market cap of Genprex Inc (GNPX)?
Genprex Inc (GNPX) has a market capitalisation of $ 3 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Genprex Inc (GNPX)?
Before investing in Genprex Inc (GNPX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.